针对老年人骨质疏松症的抗吸收疗法
Anne Sophie Sølling1, Natasha Amran Laursen1,2, Torben Harsløf1,2
1Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark.
Gerontology
|June 24, 2025
概括
在老年患者治疗骨质疏松症时,抗吸收药物是有效和安全的. 替代的施用途径可以改善这种人群的药物服药.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 骨质疏松症对老年人造成骨折和死亡的重大风险.
- 对老年骨质疏松症患者开处方抗吸收药物存在由于并发病,多药和跌倒风险的挑战.
- 对于接受长期骨质疏松症治疗的老年人来说,仔细考虑益处风险比是至关重要的.
研究的目的:
- 对老年人群中骨质疏松症的抗吸收治疗方法的疗效和安全性进行审查.
- 评估和维生素D补充剂在这个人口群体中的作用.
- 确定改善老年患者遵守治疗的策略.
主要方法:
- 系统评估已发表的临床试验,评论和元分析.
- 专注于抗吸收疗法,包括口服和注射配方.
- 评估疗效,安全性概况和坚持因素.
主要成果:
- 抗吸收疗法在骨质疏松症的老年人中显著有效降低骨折风险.
- 这些药物的安全性概况在老年人群中通常是有利的.
- 静脉注射或皮下注射可以提高患者的遵从性.
结论:
- 抗吸收疗法是对老年人骨质疏松症的推和有效治疗方法.
- 确保患者遵守是至关重要的,对于那些有坚持困难的人来说,可用的是替代的给药方法.
- 对大多数患有骨质疏松症的老年患者来说,抗吸收治疗的好处超过了风险.
相关概念视频
Osteoclasts in Bone Remodeling
3.2K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.2K
Bone Remodeling
38.6K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.6K
Bone Disorders
4.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
4.0K
Hormones and Bone Tissue
3.0K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.0K
Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524


